Calendula Officinalis Compounds Explored as Potential Therapy for KRAS Mutation-Driven Cancers

Researchers have identified Calendula officinalis, commonly known as marigold, as a potential source of anticancer agents targeting KRAS mutations. The study combines traditional herbal medicine with advanced computational science to explore alternative therapeutic strategies for cancers associated with this challenging oncogene. KRAS mutations are known for their resistance to conventional treatments, making them a significant focus in cancer research.

The findings suggest that compounds derived from Calendula officinalis may offer new approaches to addressing cancers driven by these mutations. Researchers utilized computational methods to analyze the plant’s chemical properties and their interaction with KRAS-related pathways. This discovery highlights the potential of integrating natural products into modern oncology research and opens avenues for further investigation into the use of marigold-based compounds in targeted cancer therapies.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

Related posts:

Cardinal Health VP Highlights Need for Long-Term Outcome Tracking to Justify Advanced Therapy Costs and Payment Models Analysis Calls for Expanded Clinical Roles to Help Pharmacists Reduce Medication Errors Inflammation and Metabolism Identified as Key Drivers in Heart Failure Progression Study Links Very Preterm Birth Before 32 Weeks to Higher Risks of Chronic Kidney Disease and Intellectual Disabilities

Author

GOAI